These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 26211598)

  • 1. Preclinical model for identification of therapeutic targets for CML offers clues for handling imatinib resistance.
    Molli PR; Pradhan MB; Ingle AD; Naik NR
    Biomed Pharmacother; 2015 Jul; 73():160-70. PubMed ID: 26211598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation.
    Fang Z; Jung KH; Yan HH; Kim SJ; Son MK; Rumman M; Lee H; Kim KW; Yoo HD; Hong SS
    Int J Oncol; 2015 Jul; 47(1):253-61. PubMed ID: 25963192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells.
    Chen PH; Liu AJ; Ho KH; Chiu YT; Anne Lin ZH; Lee YT; Shih CM; Chen KC
    Chem Biol Interact; 2018 Aug; 291():144-151. PubMed ID: 29890129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EphB4-VAV1 signaling pathway is associated with imatinib resistance in chronic myeloid leukemia cells.
    Zhang JF; Xu N; Du QF; Li R; Liu XL
    Blood Cells Mol Dis; 2016 Jul; 59():58-62. PubMed ID: 27282569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants.
    Lounnas N; Frelin C; Gonthier N; Colosetti P; Sirvent A; Cassuto JP; Berthier F; Sirvent N; Rousselot P; Dreano M; Peyron JF; Imbert V
    Int J Cancer; 2009 Jul; 125(2):308-17. PubMed ID: 19378338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
    Hentschel J; Rubio I; Eberhart M; Hipler C; Schiefner J; Schubert K; Loncarevic IF; Wittig U; Baniahmad A; von Eggeling F
    Int J Oncol; 2011 Sep; 39(3):585-91. PubMed ID: 21637917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adiponectin signals through Adiponectin Receptor 1 to reverse imatinib resistance in K562 human chronic myeloid leukemia cells.
    Wu S; Zheng C; Chen S; Lin B; Chen Y; Zhou W; Li Z
    Biochem Biophys Res Commun; 2015 Jan; 456(1):367-72. PubMed ID: 25475722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploitation of redox discrepancy in leukemia cells by a reactive oxygen species nanoscavenger for inducing cytotoxicity in imatinib resistant cells.
    Acharya S; Sahoo SK
    J Colloid Interface Sci; 2016 Apr; 467():180-191. PubMed ID: 26802277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
    Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
    Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells.
    Baran Y; Ural AU; Gunduz U
    Hematology; 2007 Dec; 12(6):497-503. PubMed ID: 17852433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
    Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
    Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA MALAT1 promotes cell proliferation and imatinib resistance by sponging miR-328 in chronic myelogenous leukemia.
    Wen F; Cao YX; Luo ZY; Liao P; Lu ZW
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):1-8. PubMed ID: 30366670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ZFX Facilitates Cell Proliferation and Imatinib Resistance in Chronic Myeloid Leukemia Cells.
    Wu J; Wei B; Wang Q; Ding Y; Deng Z; Lu X; Li Y
    Cell Biochem Biophys; 2016 Jun; 74(2):277-83. PubMed ID: 26912059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the ETS transcription factor GABPα is positively correlated to the BCR-ABL1/ABL1 ratio in CML patients and affects imatinib sensitivity in vitro.
    Manukjan G; Ripperger T; Santer L; von Neuhoff N; Ganser A; Schambach A; Schlegelberger B; Steinemann D
    Exp Hematol; 2015 Oct; 43(10):880-90. PubMed ID: 26072332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
    Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
    Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
    Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
    Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.